Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the Tessa News Link Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

Two common forever chemicals linked to higher incidence of ER-negative breast cancer (opens in a new tab)

news-medical.net · 2026-11-06

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 1 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim overstates the study. One of five checks out. Three claims the study doesn't address.

  • 1 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedThe authors say their findings were confirmed using a meta-analysis of prior research and suggest PFAS may influence cancer risk through non-hormonal biological pathways, though that explanation was not tested in the study.View evidenceHide evidence

Why this verdict

The profile says the meta-analysis of seven studies further supported associations, but the story’s wording that the findings were “confirmed” is stronger than the supplied evidence, especially because the pooled PFOS estimate for ER-negative breast cancer had a confidence interval including the null. The proposed non-hormonal pathway explanation is not established in the supplied abstract profile, though the story does hedge that the mechanism was not tested.

1

Study evidence

Perfluoro-n-octanoic acid (PFOA) was positively associated with ER-negative breast cancer (Q4 vs Q1).HR Q4 vs Q1 1.67 (95% CI 1.10 to 2.53); P trend = .09

“We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants.”
2

Study evidence

PFOA was associated with increased risk of ER-negative breast cancer in the meta-analysis.RR 1.30 (95% CI, 1.05 to 1.62)

“We conducted a meta-analysis of seven studies with prediagnostic blood PFAS measurements.”
Claim 2 of 5Not coveredHigher blood plasma levels of PFOA and PFOS were associated with a higher incidence of ER-negative breast cancer, but there was no clear association with breast cancer risk overall.View evidenceHide evidence

As stated67% higher rate for PFOA and 93% higher rate for PFOS in the highest-exposure groups versus the lowest

Why this verdict

The ER-negative PFOA and PFOS associations and the stated magnitudes are supported by the abstract profile: PFOA HR 1.67 and PFOS HR 1.93 for Q4 vs Q1, corresponding to 67% and 93% higher hazard/rate estimates. However, the supplied abstract profile does not report the claimed absence of a clear association with overall breast cancer risk, so that part is not verifiable at this evidence depth.

1

Study evidence

Perfluoro-n-octanoic acid (PFOA) was positively associated with ER-negative breast cancer (Q4 vs Q1).HR Q4 vs Q1 1.67 (95% CI 1.10 to 2.53); P trend = .09

“We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants.”
Claim 3 of 5Not coveredThe study drew on the Sister Study, measuring 17 PFAS in blood collected years before diagnosis among women in the United States and Puerto Rico; the article says 1,609 women developed breast cancer and 2,269 served as a comparison sample.View evidenceHide evidence

As stated50,884 women enrolled in the larger Sister Study

Why this verdict

The profile supports the core design details: a Sister Study case-cohort analysis, 17 PFAS measured in prediagnostic plasma, 1,609 breast cancer cases, and 2,269 subcohort participants. But the supplied abstract profile does not verify the larger Sister Study enrollment number of 50,884 or the United States and Puerto Rico geographic detail, so the full claim cannot be fully verified at this depth.

1

Study evidence

Perfluoro-n-octanoic acid (PFOA) was positively associated with ER-negative breast cancer (Q4 vs Q1).HR Q4 vs Q1 1.67 (95% CI 1.10 to 2.53); P trend = .09

“We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants.”
Claim 4 of 5Not coveredThe article says the work was reported in the Journal of Clinical Oncology and that more research is needed, especially on newer replacement PFAS chemicals.View evidenceHide evidence

Why this verdict

The supplied abstract profile does not include journal metadata confirming Journal of Clinical Oncology, nor does it document a recommendation focused on newer replacement PFAS chemicals. The general idea that further research is relevant is consistent with the uncertainty in the profile, but the specific story claim is not verifiable from the provided abstract-level evidence.

Claim 5 of 5SupportedWomen with higher blood levels of two common PFAS were more likely to develop ER-negative breast cancer, according to a new NIH study.View evidenceHide evidence

Why this verdict

The abstract-level profile supports an observational association: in the Sister Study case-cohort analysis, higher PFOA and PFOS quartiles were associated with higher incidence of ER-negative breast cancer. The headline wording is somewhat direct, but the claim is framed as likelihood/association from a study rather than as proven causation.

1

Study evidence

Perfluoro-n-octanoic acid (PFOA) was positively associated with ER-negative breast cancer (Q4 vs Q1).HR Q4 vs Q1 1.67 (95% CI 1.10 to 2.53); P trend = .09

“We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The PFOA ER-negative result had a borderline trend test despite a Q4-vs-Q1 confidence interval excluding the null: HR 1.67, 95% CI 1.10 to 2.53, P trend = .09.

    The story reports the relative increase but does not mention the borderline P-trend caveat, which affects interpretation of the dose-response evidence.

    From Case-cohort study (Sister Study)

  • The meta-analysis was supportive rather than uniformly definitive: pooled PFOA RR 1.30, 95% CI 1.05 to 1.62; pooled PFOS RR 1.20, 95% CI 0.91 to 1.58, with the PFOS confidence interval including the null.

    The story says the findings were confirmed by meta-analysis, but the abstract profile characterizes support and shows imprecision for PFOS.

    From Meta-analysis

  • The meta-analysis limitations available at abstract depth include missing details on search strategy, inclusion/exclusion criteria, number of studies per pooled estimate, statistical model, heterogeneity, publication bias, and limited receptor-status subgroup availability.

    The story mentions that more research is needed, but it does not acknowledge these meta-analysis-specific limitations from the supplied profile.

    From Meta-analysis

2 things the story did carry across
  • The primary paper evidence is observational human research: a case-cohort study within the Sister Study using prediagnostic plasma PFAS measurements and sampling-weighted Cox models adjusted for confounders and coexposures.
  • The central positive findings were for PFOA and PFOS with ER-negative breast cancer: PFOA Q4 vs Q1 HR 1.67 and PFOS Q4 vs Q1 HR 1.93.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEstimate associations between prediagnostic plasma PFAS concentrations and incident breast cancer in the Sister Study, including analyses by hormone receptor status (ER-negative and ER-positive).Case-cohort study (Sister Study)Expand

In plain English

Case-cohort analysis within the Sister Study (1,609 breast cancer cases; 2,269 subcohort participants) relating 17 prediagnostic plasma PFAS measured by LC–HRMS to incident breast cancer, with oversampling of ER-negative cases and sampling-weighted Cox models adjusted for confounders and coexposures; results indicate positive associations of PFOA and PFOS with ER-negative tumors and supportive meta-analysis findings.

Key findings

  • Perfluoro-n-octanoic acid (PFOA) was positively associated with ER-negative breast cancer (Q4 vs Q1).HR Q4 vs Q1 1.67 (95% CI 1.10 to 2.53); P trend = .09
  • Perfluorooctane-1-sulfonic acid (PFOS) was positively associated with ER-negative breast cancer (Q4 vs Q1).HR Q4 vs Q1 1.93 (95% CI 1.15 to 3.22); P trend = .01
“We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants.”
2secondary dataSynthesize existing prospective epidemiologic evidence on prediagnostic blood PFAS and breast cancer risk via a meta-analysis of prior studies, including receptor-status–specific results where available.Meta-analysisExpand

In plain English

Meta-analysis of seven studies with prediagnostic blood PFAS measurements pooled relative risks for PFOA and PFOS with respect to ER-negative breast cancer; reported pooled RRs were 1.30 (95% CI, 1.05 to 1.62) for PFOA and 1.20 (95% CI, 0.91 to 1.58) for PFOS.

Key findings

  • PFOA was associated with increased risk of ER-negative breast cancer in the meta-analysis.RR 1.30 (95% CI, 1.05 to 1.62)
  • PFOS showed a pooled estimate suggestive of increased risk of ER-negative breast cancer, though the confidence interval included the null.RR 1.20 (95% CI, 0.91 to 1.58)
“We conducted a meta-analysis of seven studies with prediagnostic blood PFAS measurements.”
What this piece can’t prove
  • Abstract does not report the meta-analysis search strategy, inclusion/exclusion criteria, number of studies contributing to each pooled estimate, statistical model (fixed vs random effects), measures of heterogeneity, or assessment of publication bias.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 36 candidate papers

And 30 more candidates considered.